Naltrexone And Bupropion
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
Orexigen Therapeutics, Inc · Phase 2/3 · Completed · Enrollment 3
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Naltrexone/Bupropion | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Naltrexone/Bupropion: endpoint not reported
- Placebo: endpoint not reported